Zydus Cadila seeks regulatory approval for clinical trials of antibody cocktail
Shortpedia
Content Team
Image Credit: Shortpedia
India-based Zydus Cadila has filed for regulatory approval for conducting clinical trials of its antibody cocktail for the treatment of mild coronavirus cases. "At this juncture, there is a critical need to explore safer and more efficacious treatments to combat COVID," Zydus Cadila's managing director, Sharvil Patel, said. The antibody cocktail ZRC-3308 is a cocktail of two monoclonal antibodies.
